Abstract
Incorporation of drugs into particles can improve their therapeutic effectiveness. Solubility, half-life time, targeting, and the release of the drug can be modified by the encapsulation into a particle. Histone deacetylase inhibitors have a great potential to be used as therapeutics for many different diseases. In this chapter, we describe the inclusion of the low molar mass HDACi Ex527 into polymer-based particles and liposomes.
Keywords:
Acetalated dextran; Cellular uptake; Ex527; Histone deacetylase inhibitor; Liposomes; PLGA.
MeSH terms
-
Acetylation
-
Carbazoles / chemistry
-
Carbazoles / pharmacology*
-
Cell Survival / drug effects
-
Dextrans / chemistry
-
Drug Compounding / methods*
-
Flow Cytometry
-
Fluorescent Dyes / chemistry
-
HEK293 Cells
-
Half-Life
-
Histone Deacetylase Inhibitors / chemistry
-
Histone Deacetylase Inhibitors / pharmacology*
-
Humans
-
Lactic Acid / chemistry
-
Liposomes / chemistry
-
Liposomes / metabolism*
-
Phosphatidylcholines / chemistry
-
Polyglycolic Acid / chemistry
-
Polylactic Acid-Polyglycolic Acid Copolymer
-
Rhodamines / chemistry
-
Solubility
Substances
-
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
-
Carbazoles
-
Dextrans
-
Fluorescent Dyes
-
Histone Deacetylase Inhibitors
-
Liposomes
-
Phosphatidylcholines
-
Rhodamines
-
Polylactic Acid-Polyglycolic Acid Copolymer
-
Polyglycolic Acid
-
Lactic Acid
-
rhodamine B